Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:BGXX NASDAQ:GRI NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$12.72+0.7%$8.67$6.00▼$190.50$8.55M1.2179,283 shs28,363 shsBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsGRIGRI Bio$1.91-3.0%$1.62$1.10▼$30.43$4.96M-1.453.42 million shs272,542 shsNERVMinerva Neurosciences$2.83+29.8%$2.15$1.15▼$3.29N/A-0.3210,114 shs8.91 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap-4.46%+14.82%+60.48%-40.14%-92.13%BGXXBright Green0.00%0.00%0.00%0.00%+16.50%GRIGRI Bio-1.50%-4.37%+18.67%+18.67%-66.55%NERVMinerva Neurosciences+1.87%+3.81%-7.23%+27.33%-17.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$12.72+0.7%$8.67$6.00▼$190.50$8.55M1.2179,283 shs28,363 shsBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsGRIGRI Bio$1.91-3.0%$1.62$1.10▼$30.43$4.96M-1.453.42 million shs272,542 shsNERVMinerva Neurosciences$2.83+29.8%$2.15$1.15▼$3.29N/A-0.3210,114 shs8.91 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap-4.46%+14.82%+60.48%-40.14%-92.13%BGXXBright Green0.00%0.00%0.00%0.00%+16.50%GRIGRI Bio-1.50%-4.37%+18.67%+18.67%-66.55%NERVMinerva Neurosciences+1.87%+3.81%-7.23%+27.33%-17.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 2.00Hold$320.002,415.72% UpsideBGXXBright Green 0.00N/AN/AN/AGRIGRI Bio 2.33Hold$22.501,078.01% UpsideNERVMinerva Neurosciences 1.50Reduce$5.0076.68% UpsideCurrent Analyst Ratings BreakdownLatest GRI, NERV, BCTX, and BGXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BCTXBriacell TherapWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GRIGRI BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025BCTXBriacell TherapWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025GRIGRI BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/22/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$34.00 ➝ $35.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A($22.02) per shareN/ABGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/AGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.27 per share10.43($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$83.18N/AN/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)BGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/AGRIGRI Bio-$8.21M-$11.560.00N/AN/AN/A-327.62%-191.40%11/13/2025 (Estimated)NERVMinerva Neurosciences$1.44M$1.481.91N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)Latest GRI, NERV, BCTX, and BGXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025NERVMinerva Neurosciences-$0.35N/AN/AN/AN/AN/A10/27/2025N/ABCTXBriacell Therap-$12.11N/AN/AN/AN/AN/A8/14/2025Q2 2025GRIGRI Bio-$1.31-$1.31N/A-$1.31N/AN/A8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41BGXXBright GreenN/A0.010.01GRIGRI BioN/A2.412.41NERVMinerva NeurosciencesN/A6.156.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%BGXXBright Green7.83%GRIGRI Bio33.95%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%BGXXBright Green62.55%GRIGRI Bio0.87%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap8680,000639,000No DataBGXXBright Green2191.17 million71.59 millionNo DataGRIGRI Bio12.52 million2.49 millionNot OptionableNERVMinerva Neurosciences9N/AN/ANot OptionableGRI, NERV, BCTX, and BGXX HeadlinesRecent News About These CompaniesMinerva Neurosciences Stock Rises on Strategic Alternatives ReviewAugust 14, 2025 | marketwatch.comStocks to Watch: Gambling.com, GrabAGun, Minerva NeurosciencesAugust 14, 2025 | marketwatch.comMinerva Neurosciences Provides Business Updates and Second Quarter Financial ResultsAugust 14, 2025 | globenewswire.comChandigarh: Minerva enter knockout stage of Gothia Cup 2025July 17, 2025 | msn.comMinerva CEO navigates 'nightmare' lab market to secure new HQ in WoburnJuly 16, 2025 | bizjournals.comMinerva University Named World's Most Innovative University for Fourth Consecutive YearJuly 15, 2025 | uk.finance.yahoo.comFree concert on Minerva’s Municipal Park StageJuly 14, 2025 | morningjournalnews.comMHelsinki Cup: Minerva Academy in Round-16 with thumping 7-0 winJuly 14, 2025 | msn.comMinerva narrowly fell short in final, but won hearts with historic Helsinki Cup campaignJuly 13, 2025 | english.newsnationtv.comEMinerva Academy FC: Defying Odds and Dazzling Europe in Helsinki Cup-2025July 13, 2025 | devdiscourse.comDHelsinki Cup: Minerva Academy in semi-finals, two Finland clubs eliminatedJuly 12, 2025 | english.newsnationtv.comEMinerva Neurosciences Inc. (NERV) Stock Price Today - WSJJuly 11, 2025 | wsj.comMinerva registers fourth win in Helsinki CupJuly 10, 2025 | msn.comHelsinki Cup: Minerva Academy logs twin victoriesJuly 10, 2025 | msn.comMinerva Academy FC's Triumph: An Unstoppable Force in Helsinki Cup 2025July 10, 2025 | devdiscourse.comDHelsinki Cup: Minerva registered its fourth win, creating history by winning the match 9-0July 10, 2025 | news.webindia123.comNMinerva High School Athletic Hall of Fame announces Class of 2025 membersJuly 10, 2025 | msn.comValCUN installs Minerva metal Additive Manufacturing machine at Johns Hopkins UniversityJuly 8, 2025 | metal-am.comMMinerva Avenue Charting Next Steps Following Sudden FireJuly 8, 2025 | msn.comFire destroys popular North Nashville nightclub Minerva AvenueJuly 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025These 3 Stocks Boosting Buybacks Have Rallying PotentialBy Leo Miller | September 22, 2025Powering Up: A Buy Rating Signals GE Vernova's AI TailwindsBy Jeffrey Neal Johnson | September 17, 2025GRI, NERV, BCTX, and BGXX Company DescriptionsBriacell Therap NASDAQ:BCTX$12.72 +0.09 (+0.71%) Closing price 04:00 PM EasternExtended Trading$12.90 +0.18 (+1.45%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Bright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.GRI Bio NASDAQ:GRI$1.91 -0.06 (-3.05%) As of 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Minerva Neurosciences NASDAQ:NERV$2.83 +0.65 (+29.82%) Closing price 04:00 PM EasternExtended Trading$2.75 -0.08 (-2.86%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
